Posaconazole plasma concentrations in critically ill patients

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 387-392

  Ray, John ^a   Campbell, Lewis ^b   Rudham, Sam ^a   Nguyen, Quoc ^a   Marriott, Deborah ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Antifungal; Critically ill; Posaconazole; Therapeutic drug monitoring

Indexed keywords

ERYTHROMYCIN; PHENYTOIN; POSACONAZOLE; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CLINICAL ARTICLE; CRITICAL ILLNESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MYCOSIS; PRIORITY JOURNAL; STEADY STATE;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; TRIAZOLES;

EID: 80051792869     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821fb197     Document Type: Article

References (28)

1. Groll AH, Walsh TJ. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses. 2006;49(suppl 1):7-16. (Pubitemid 44370096)
2. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007; 44:2-12. (Pubitemid 44968977)
3. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001; 45:857-869. (Pubitemid 32182037)
4. Products on application (NDA) 022027 (NOXAFIL). Online at http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/022027lbl.pdf. Accessed January 10, 2009.
5. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47:2788-2795. (Pubitemid 37040249)
6. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658-666. (Pubitemid 43190980)
7. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804-808. (Pubitemid 38280328)
8. Krishna G, Moton A, Ma L, et al. Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole [abstract no. 1264]. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain, 2008.
9. Frampton JE, Scott LJ. Posaconazole: a review of its use in the treatment of invasive fungal infections. Drugs. 2008;68:993-1016. (Pubitemid 351652926)
10. Dodds Ashley ES, Varkey JB, Krishna G, et al. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother. 2009;53:2960-2964.
11. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic haematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1927-1936.
12. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother. 2007;51:495-502. (Pubitemid 46185266)
13. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin. 2007;23:1415-1422. (Pubitemid 46998449)
14. Marriott D, Levy R, Doyle T, et al. Posaconazole-induced topiramate toxicity. Ann Int Med. 2009;151:143.
15. Bruggemann RJM, Alfenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441-1458.
16. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825-834. (Pubitemid 46849426)
17. Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin. 2009;25:701-707.
18. Conte J, Golden J, Krishna G, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady-state in healthy subjects. Antimicrob Agents Chemother. 2009;53:703-707.
19. Thompson G, Rinaldi M, Patterson T, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother. 2009;53:2223-2224.
20. Jang S, Colangelo P, Gobburu J. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharm Ther. 2010;88:115-119.
21. Metheny NA, Schallom ME, Edwards SJ. Effect of gastrointestinal motility and feeding tube site on aspiration risk in critically ill patients: a review. Heart Lung. 2004;33:131-145. (Pubitemid 38857950)
22. Wenning L, Hanley W, Brainard D, et al. Effect of Rifampicin a potent inducer of drug-metabolising enzymes on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852-2856.
23. Chen SC, Marriott D, Playford EG, et al. Candidaemia with uncommon candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect. 2009;15: 662-669.
24. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139:519-531. (Pubitemid 350043811)
25. Heyland D, Cook D, Winder B, et al. Enteral nutrition in the critically ill patient: a prospective survey. Crit Care Med. 1995;23:1055-1060.
26. Simpson F, Doig GS. Parenteral vs enteral nutrition in the critically ill patient: a meta-analysis of trials using the intention to treat principle. Int Care Med. 2004;31:12-23. (Pubitemid 40174278)
27. Zimmermann T, Yeates R, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46:147-150. (Pubitemid 24101333)
28. Chapman M, Nguyen N, Fraser R. Gastrointestinal motility and prokinetics in the critically ill. Curr Opin Crit Care. 2007;13:187-194. (Pubitemid 46328334)